Targeting prodromal Alzheimer’s disease: too late for prevention?
نویسنده
چکیده
Prodromal Alzheimer’s disease is a novel area of research, with clinical research definitions still under development. The LipiDiDiet trial,1 published in The Lancet Neurology, was one of the first completed trials based on the International Working Group (IWG-1) criteria for prodromal Alzheimer’s disease.2 The study was a non-pharmacological intervention (medical food Souvenaid) in prodromal Alzheimer’s disease.
منابع مشابه
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
The majority of putative disease-modifying treatments in development for Alzheimer's disease are directed against the amyloid-β (Aβ) peptide. Among the anti-Aβ therapeutic approaches, the most extensively developed is immunotherapy-specifically, passive immunization through administration of exogenous monoclonal antibodies (mAbs). Although testing of mAbs has been fraught with failure and confu...
متن کاملDistinct F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease
Patients with Alzheimer’s disease can present with different clinical phenotypes. Individuals with late-onset Alzheimer’s disease (465 years) typically present with medial temporal lobe neurodegeneration and predominantly amnestic symptomatology, while patients with early-onset Alzheimer’s disease (565 years) exhibit greater neocortical involvement associated with a clinical presentation includ...
متن کامل11 ECKERT_04 LORD_c
Preventive strategies for late-onset Alzheimer’s disease (AD) should start early at a prodromal stage. Mitochondrial dysfunction has been found to play an important role in the initiation of both aging and the pathogenesis of Alzheimer’s disease. Curcumin, a widely used spice and food-coloring agent, is a polyphenol derived from the rhizome of Curcuma longa. It is known to have anti-oxidant, an...
متن کاملPotential Utility of Practice Effects in Preventive Trials.
By the time an individual fulfills clinical cr i ter ia for Alzheimer’s disease (AD) dementia, extensive and likely irreversible neurodegeneration has already occurred. While we might be able to slow disease progression at this late stage, there is minimal likelihood of completely restoring brain and cognitive function once extensive neurodegeneration is present. Accordingly, most clinical tria...
متن کاملDevelopment of the CHARIOT Research Register for the Prevention of Alzheimer’s Dementia and Other Late Onset Neurodegenerative Diseases
BACKGROUND Identifying cognitively healthy people at high risk of developing dementia is an ever-increasing focus. These individuals are essential for inclusion in observational studies into the natural history of the prodromal and early disease stages and for interventional studies aimed at prevention or disease modification. The success of this research is dependent on having access to a well...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 16 شماره
صفحات -
تاریخ انتشار 2017